Huifen Chen

Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.

Anthony M Giannetti, Ping Wu, Brandon J. Bravo, 2014, Journal of medicinal chemistry.

Structure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis.

Kevin Chen, Ping Wu, Stephen Schmidt, 2015, ACS medicinal chemistry letters.

Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling.

Jason Drummond, Xingrong Liu, Yichin Liu, 2012, Journal of medicinal chemistry.

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Wei Zhou, William F. Forrest, Sherry Heldens, 2012, Molecular Cancer Therapeutics.

Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.

Yuntao Song, Bruce Auerbach, Lisa Dillon, 2007, Bioorganic & medicinal chemistry letters.

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Ariana Peck, Shiuh-Ming Luoh, Steve Price, 2013, Nature.

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.

Anthony M Giannetti, Ping Wu, Brandon J. Bravo, 2014, Bioorganic & medicinal chemistry letters.